Evaluation of PECAM-1 Expression and Microvessel Density in Gastric Adenocarcinoma: a Cross-sectional Study
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Gastric adenocarcinoma is the fifth most prevalent malignancy globally and ranks sixth in Bangladesh, representing a significant oncological and public health challenge. Gaining in depth knowledge about the tumor microenvironment, particularly the mechanisms of tumor-induced angiogenesis, is essential for the development of more precise and effective targeted therapies. Microvessel density (MVD) serves as a widely recognized measure of angiogenic activity and can be reliably assessed using immunohistochemical staining for PECAM-1 (CD31), a highly specific marker of vascular endothelial cells.
Methods
This cross-sectional observational study was conducted in the Department of Pathology, Satkhira Medical College, from April 2024 to March 2025. A total of 50 cases of invasive gastric adenocarcinoma were included. Routine Hematoxylin and Eosin (H&E) staining was performed for Lauren classification. Immunohistochemistry for PECAM-1 was conducted to highlight microvessels.
Result
Among 50 cases, intestinal-type adenocarcinoma was more frequent than diffuse type. High MVD was observed in 58.1% of intestinal-type cases and 36.8% of diffuse-type cases. The difference in MVD between intestinal and diffuse types was statistically significant (p < 0.05), suggesting higher angiogenic activity in intestinal-type tumors.
Conclusion
This study demonstrates that PECAM-1 positive MVD is significantly higher in the intestinal subtype of gastric adenocarcinoma compared to the diffuse subtype. These findings indicate a more angiogenically active tumor microenvironment in intestinal-type tumors, potentially correlating with greater invasive potential and metastatic behavior. PECAM-1 immunostaining provides a valuable tool for quantifying tumor angiogenesis and may serve as a prognostic marker or a basis for anti-angiogenic therapeutic targeting in gastric cancer management.
